文献速递乳腺癌

变构PI3Kα抑制剂克服由继发性PIK3CA突变介导的变位性抑制剂靶点耐药

Allosteric PI3Kα Inhibition Overcomes On-target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA Mutations.
PubMed 文献 · Cancer Discov · 2024-01-01

在39例晚期乳腺癌患者中,通过连续液体活检和快速尸检发现,50%的患者在PI3Kα抑制剂获得性耐药后出现PI3K通路基因组改变,包括PTEN缺失和AKT1激活突变。新出现的继发性PIK3CA耐药突变改变抑制剂结合口袋,但所有突变诱导的耐药均可被新型变构泛突变选择性PI3Kα抑制剂RLY-2608克服。

要点

  • 39例晚期乳腺癌患者中,50%在PI3Kα抑制剂耐药后出现PI3K通路基因组改变。
  • 继发性PIK3CA耐药突变改变抑制剂结合口袋,对PI3Kα选择性抑制剂与泛PI3K抑制剂影响不同。
  • 所有突变诱导的耐药均可被变构泛突变选择性PI3Kα抑制剂RLY-2608克服。

核心结论

  • PI3K通路基因组改变是PI3Kα抑制剂获得性耐药的主要模式,继发性PIK3CA耐药突变可被变构PI3Kα抑制剂RLY-2608克服。

研究设计与样本

  • 对39例接受PI3Kα抑制剂治疗后出现获得性耐药的晚期乳腺癌患者进行连续液体活检和快速尸检。

主要发现

  • 39例患者中50%获得PI3K通路基因组改变,包括PTEN缺失和AKT1激活突变。
  • 鉴定出改变抑制剂结合口袋的新发继发性PIK3CA耐药突变,部分突变对PI3Kα选择性抑制剂与泛PI3K抑制剂效果不同。
  • 所有突变诱导的耐药均可被变构泛突变选择性PI3Kα抑制剂RLY-2608克服。

关键数值与推荐

  • PIK3CA突变发生于约8%的癌症,包括约40%的HR阳性乳腺癌。
  • 阿培利司联合氟维司群获FDA批准用于HR阳性乳腺癌。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: PIK3CA mutations occur in ∼8% of cancers, including ∼40% of HR-positive breast cancers, where the PI3K-alpha (PI3Kα)-selective inhibitor alpelisib is FDA approved in combination with fulvestrant. Although prior studies have identified resistance mechanisms, such as PTEN loss, clinically acquired resistance to PI3Kα inhibitors remains poorly understood. Through serial liquid biopsies and rapid autopsies in 39 patients with advanced breast cancer developing acquired resistance to PI3Kα inhibitors, we observe that 50% of patients acquire genomic alterations within the PI3K pathway, including PTEN loss and activating AKT1 mutations. Notably, although secondary PIK3CA mutations were previously reported to increase sensitivity to PI3Kα inhibitors, we identified emergent secondary resistance mutations in PIK3CA that alter the inhibitor binding pocket. Some mutations had differential effects on PI3Kα-selective versus pan-PI3K inhibitors, but resistance induced by all mutations could be overcome by the novel allosteric pan-mutant-selective PI3Kα-inhibitor RLY-2608. Together, these findings provide insights to guide strategies to overcome resistance in PIK3CA-mutated cancers. SIGNIFICANCE: In one of the largest patient cohorts analyzed to date, this study defines the clinical landscape of acquired resistance to PI3Kα inhibitors. Genomic alterations within the PI3K pathway represent a major mode of resistance and identify a novel class of secondary PIK3CA resistance mutations that can be overcome by an allosteric PI3Kα inhibitor. See related commentary by Gong and Vanhaesebroeck, p. 204 . See related article by Varkaris et al., p. 240 . This article is featured in Selected Articles from This Issue, p. 201.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Varkaris A, Fece de la Cruz F, Martin EE, et al. Allosteric PI3Kα Inhibition Overcomes On-target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA Mutations. Cancer Discov. 2024. PMID: 37916958. doi:10.1158/2159-8290.CD-23-0704

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。